Review Article

Possible Role of the Transglutaminases in the Pathogenesis of Alzheimer’s Disease and Other Neurodegenerative Diseases

Antonio Martin, Giulia De Vivo, and Vittorio Gentile

Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli 16, 80138 Naples, Italy

Correspondence should be addressed to Vittorio Gentile, vittorio.gentile@unina2.it

Received 23 November 2010; Accepted 5 January 2011

Copyright © 2011 Antonio Martin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transglutaminases are ubiquitous enzymes which catalyze posttranslational modifications of proteins. Recently, transglutaminase-catalyzed post-translational modification of proteins has been shown to be involved in the molecular mechanisms responsible for human diseases. Transglutaminase activity has been hypothesized to be involved also in the pathogenetic mechanisms responsible for several human neurodegenerative diseases. Alzheimer’s disease and other neurodegenerative diseases, such as Parkinson’s disease, supranuclear palsy, Huntington’s disease, and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. This paper focuses on the possible molecular mechanisms by which transglutaminase activity could be involved in the pathogenesis of Alzheimer’s disease and other neurodegenerative diseases, and on the possible therapeutic effects of selective transglutaminase inhibitors for the cure of patients with diseases characterized by aberrant transglutaminase activity.

1. Biochemistry of the Transglutaminases

Transglutaminases (TGs, E.C. 2.3.2.13) are a family of enzymes (Table 1) which catalyze irreversible posttranslational modifications of proteins. Examples of TG-catalyzed reactions include (I) acyl transfer between the γ-carboxamide group of a protein/polypeptide glutaminyl residue and the ε-amino group of a protein/polypeptide lysyl residue; (II) attachment of a polyamine to the γ-carboxamide of a glutaminyl residue; (III) deamidation of the γ-carboxamide group of a protein/polypeptide glutaminyl residue (Figure 1) [1, 2]. The reactions catalyzed by TGs occur by a two-step mechanism (Figure 2). The transamidating activity of TGs is activated by the binding of Ca²⁺, which exposes an active-site cysteine residue. This cysteine residue reacts with the γ-carboxamide of a glutaminyl acceptor residue either on the same protein/polypeptide or between two proteins/polypeptides [3]. If there is no primary amine present, water may act as the attacking nucleophile, resulting in the deamidation of glutaminyl residues to glutamyl residues (Figure 2, Step 2). If the primary amine is donated by the ε-amino group of a lysyl residue in a protein/polypeptide, an Nε-(γ-L-glutamyl)-L-lysine (GGEL) isopeptide bond is formed (Figure 1, example (a)). On the other hand, if a polyamine or another primary amine (e.g., histamine) acts as the amine donor, a γ-glutamylpolyamine (or γ-glutamylamine) residue is formed (Figure 1, example (b)). It is also possible for a polyamine to act as an N,N-bis-(γ-L-glutamyl) polyamine bridge between two glutaminyl acceptor residues either on the same protein/polypeptide or between two proteins/polypeptides [3]. If there is no primary amine present, water may act as the attacking nucleophile, resulting in the deamidation of glutaminyl residues to glutamyl residues (Figure 1, example (c)). It is worthwhile noting that two of these reactions, in particular, the deamidation of peptides obtained from the digestion of the gliadin, a protein present in wheat, and the Nε-(γ-L-glutamyl)-L-lysine (GGEL) isopeptide formation between these peptides and “tissue” transglutaminase (TG2 or tTG), have been recently shown to cause the formation of new antigenic epitopes which are responsible of immunological reactions during the celiac disease (CD), one of the most...
Table 1: TG enzymes and their biological functions when known.

| TG         | Physiological role                               | Gene map location | Reference |
|------------|--------------------------------------------------|-------------------|-----------|
| Factor XIIIa | Blood clotting                                  | 6p24-25           | [10]      |
| TG 1 (Keratinocyte TG, kTG) | Skin differentiation                          | 14q11.2           | [11]      |
| TG 2 (Tissue TG, tTG, cTG) | Apoptosis, cell adhesion, signal transduction    | 20q11-12          | [12]      |
| TG 3 (Epidermal TG, eTG) | Hair follicle differentiation                    | 20p11.2           | [13]      |
| TG 4 (Prostate TG, pTG) | Suppression of sperm immunogenicity             | 3q21-2            | [14]      |
| TG 5 (TG X) | Epidermal differentiation                       | 15q15.2           | [15]      |
| TG 6 (TG Y) | Unknown function                                | 20p13             | [15]      |
| TG 7 (TG Z) | Unknown function                                | 15q15.2           | [15]      |

Figure 1: Transglutaminase-catalyzed reactions. Examples of TG-catalyzed reactions: (a) acyl transfer between the γ-carboxamide group of a protein/polypeptide glutaminyl residue and the ε-amino group of a protein/polypeptide lysyl residue; (b) attachment of a polyamine to the carboxamide group of a glutaminyl residue; (c) deamidation of the γ-carboxamide group of a protein/polypeptide glutaminyl residue.

common human autoimmune diseases [4, 5]. The reactions catalyzed by TGs occur with little change in free energy and hence should theoretically be reversible. However, under physiological conditions the cross linking reactions catalyzed by TGs are usually irreversible. This irreversibility partly results from the metabolic removal of ammonia from the system and from thermodynamic considerations resulting from altered protein conformation. Some scientific reports suggest that TGs may be able to catalyze the hydrolysis of Nε-(γ-L-glutamyl)-L-lysine cross-links (GGEL) isopeptide bonds in some soluble cross-linked proteins. Furthermore, it is likely that TGs can catalyze the exchange of polyamines onto proteins [2]. In some TGs, other catalytic activities, such as the ability to hydrolyze GTP (or ATP) into GDP (or ADP) and inorganic phosphate, a protein disulfide isomerase activity, a serine/threonine kinase activity, and an esterification activity, are often present [6–9].

2. Multiple Biological Activities of the Transglutaminases

Experimental evidences indicate that some TGs are multifunctional proteins with distinct and regulated enzymatic activities. In fact, under physiological conditions, the transamidation activity of TGs is latent [16], while other activities, recently identified, could be present. For example, in some pathophysiological states, when the concentration of Ca²⁺ increases, the crosslinking activity of TGs may
contribute to important biological processes. As previously described, one of the most intriguing properties of some TGs, such as TG2, is the ability to bind and hydrolyze GTP and, furthermore, to bind to GTP and Ca$^{2+}$. GTP and Ca$^{2+}$ regulate its enzymatic activities, including protein cross-linking, in a reciprocal manner; the binding of Ca$^{2+}$ inhibits GTP-binding and GTP-binding inhibits the transglutaminase cross-linking activity of the TG2 [6]. Interestingly, TG2 shows no sequence homology with heterotrimeric or low-molecular-weight G-proteins, but there is evidence that TG2 (TG2/Gha) is involved in signal transduction, and, therefore, TG2/Gha should also be classified as a large molecular weight G-protein. Other studies, along with ours, showed that TG2/Gha can mediate the activation of phospholipase C (PLC) by the $\beta_{10}$-adrenergic receptor [17] and can modulate adenyl cyclase activity [18]. TG2/Gha can also mediate the activation of the $\delta_1$ isoform of PLC and of maxi-K channels [19]. Interestingly, the signaling function of TG2/Gha is preserved even with the mutagenic inactivation of its crosslinking activity by the mutation of the active site cysteine residue [20]. Evidence of a pathophysiological role of the TGs in cell signaling, in disulfide isomerase activity, and in other biological functions, is lacking to date.

3. Molecular Biology of the Transglutaminases

At least eight different TGs, distributed in the human body, have been identified (Table 1). Complex mechanisms regulating the gene expression of TGs, both at transcriptional and translational levels, determine a complex but precise distribution of these enzymes in a cell and/or a tissue [21]. Such complex gene expression reflects the physiological roles that these enzymes play in both the intracellular and extracellular compartments. In the nervous system, for example, several forms of TGs are simultaneously expressed [15, 22, 23]. Moreover, several alternative splice variants of TGs, mostly in the 3′-end region, have been identified. Interestingly, some of them are differently expressed in human pathologies, such as Alzheimer’s disease (AD) [24]. On the basis of their ubiquitous expression and their biological roles, we may speculate that the absence of these enzymes would be lethal. However, this does not always seem to be the case, since, for example, null mutants of the TG2 are usually phenotypically normal at birth [25]. This result may be explained by the multiple expressions of other TG genes that could be substituting the missing isoform.

Bioinformatic studies have shown that the primary structures of human TGs share some identities in only few regions, such as the active site and the calcium-binding regions. However, high sequence conservation and, therefore, a high degree of preservation of residue secondary structure among these enzymes play in both the intracellular and extracellular compartments. In the nervous system, for example, several forms of TGs are simultaneously expressed [15, 22, 23]. Moreover, several alternative splice variants of TGs, mostly in the 3′-end region, have been identified. Interestingly, some of them are differently expressed in human pathologies, such as Alzheimer’s disease (AD) [24]. On the basis of their ubiquitous expression and their biological roles, we may speculate that the absence of these enzymes would be lethal. However, this does not always seem to be the case, since, for example, null mutants of the TG2 are usually phenotypically normal at birth [25]. This result may be explained by the multiple expressions of other TG genes that could be substituting the missing isoform.

Bioinformatic studies have shown that the primary structures of human TGs share some identities in only few regions, such as the active site and the calcium-binding regions. However, high sequence conservation and, therefore, a high degree of preservation of residue secondary structure among TG2, TG3, and FXIIIa indicate that these TGs all share four-domain tertiary structures which could be similar to those of other TGs [26].

4. Transglutaminases and Alzheimer’s Disease

Numerous scientific reports suggest that TG activity is involved in the pathogenesis of Alzheimer’s disease and other neurodegenerative diseases. To date, however, definitive experimental findings about the role of these enzymes in the development of these neurological diseases have not yet been obtained. Protein aggregates in affected brain regions are histopathological hallmarks of Alzheimer’s disease and many other neurodegenerative diseases [27]. More than 20 years ago, Selkoe et al. [28] suggested that TG activity might contribute to the formation of protein aggregates in AD brain. In support of this hypothesis, tau protein has been shown to be an excellent in vitro substrate of TGs [29–32], and GGEL cross-links have been found in the neurofibrillar tangles and paired helical filaments of AD brains [33, 34]. In addition to these experimental findings, it has been shown that TGs and transglutaminase-catalyzed cross-links colocalize with pathological lesions in Alzheimer’s disease brain [34–36]. Interestingly, a recent work showed the presence of bis $\gamma$-glutamyl putrescine in
Thus far, there have been no long-term effective treatments for human neurodegenerative diseases, then the possibility that selective TG inhibitors may be of clinical benefit has been seriously considered. In this respect, some encouraging results have been obtained with TG inhibitors in preliminary studies with different biological models of CAG-expansion diseases. For example, cystamine (Figure 4) is a potent in vitro inhibitor of enzymes that require an unmodified cysteine at the active site [59]. Inasmuch as TGs contain a crucial active-site cysteine, cystamine has the potential to inhibit these enzymes by disulfide interchange reactions. A disulfide interchange reaction results in the formation of cysteamine and a cysteamine-cysteine mixed disulfide residue at the active site. Recent studies have shown that cystamine decreases the number of protein inclusions in transfected cells expressing the atrophin protein containing a pathological-length polyglutamine domain, responsible for the Dentato-Rubro-Pallido-Luysian Atrophy (DRPLA) [60]. In other studies, cystamine administration to HD-transgenic mice resulted in an increase in life expectancy and amelioration of neurological symptoms [61, 62]. Neuronal inclusions were decreased in one of these studies [62]. Although all these scientific reports seem to support the hypothesis of a direct role of TG activity in the pathogenesis of the polyglutamine diseases, cystamine is also found to act in the HD-transgenic mice by mechanisms other than the inhibition of TGs, such as the inhibition of Caspases [63], suggesting that this compound can have an additive effect in the therapy of HD. The pharmacodynamics and pharmacokinetics of cystamine, therefore, should be carefully investigated in order to confirm the same effectiveness in patients with neurodegenerative diseases. Another critical problem in the use of TG inhibitors in treating neurological diseases relates to the fact that, as previously reported, the human brain contains at least four TGs, including TG1, 2, 3 [23], and possibly TG6 [64], and a strong nonspecific inhibitor of TGs might also inhibit plasma Factor XIII, causing a bleeding disorder. Therefore, from a number of standpoints, it would seem that a selective inhibitor, which discriminates between TGs, would be preferable to an indiscriminate TG inhibitor. In fact, although most of the TG activity in mouse brain, at least as assessed by

5. Transglutaminases as Potential Therapeutic Targets of Neurodegenerative Diseases

Figure 3: Possible mechanisms responsible for protein aggregate formation catalyzed by TGs.

Figure 4: Chemical structure of cystamine.
### Table 2: List of polyglutamine (CAG-expansion) diseases.

| Disease | Sites of neuropathology | CAG triplet number | Gene product (Intracellular localization of protein deposits) | Reference |
|---------|-------------------------|-------------------|---------------------------------------------------------------|-----------|
| Corea major or Huntington’s disease (HD) | Striatum (medium spiny neurons) and cortex in late stage | 6–35 | Huntingtin (n, c) | [49] |
| Spinocerebellar Ataxia Type 1 (SCA1) | Cerebellar cortex (Purkinje cells), dentate nucleus, and brainstem | 6–39 | Ataxin-1 (n, c) | [50] |
| Spinocerebellar Ataxia Type 2 (SCA2) | Cerebellum, pontine nuclei, substantia nigra | 15–29 | Ataxin-2 (c) | [51] |
| Spinocerebellar Ataxia Type 3 (SCA3) or Machado-Joseph disease (MJD) | Substantia nigra, globus pallidus, pontine nucleus, cerebellar cortex | 13–42 | Ataxin-3 (c) | [52] |
| Spinocerebellar Ataxia Type 6 (SCA6) | Cerebellum and mild brainstem atrophy | 4–18 | Calcium channel subunit (α1A) (m) | [53] |
| Spinocerebellar Ataxia Type 7 (SCA7) | Photoreceptor and bipolar cells, cerebellar cortex, brainstem | 7–17 | Ataxin-7 (n) | [54] |
| Spinocerebellar Ataxia Type 12 (SCA12) | Cortical, cerebellar atrophy | 7–32 | Brain-specific regulatory subunit of protein phosphatase PP2A (?) | [55] |
| Spinocerebellar Ataxia Type 17 (SCA17) | Gliosis and neuronal loss in the Purkinje cell layer | 29–42 | TATA-binding protein (TBP) (n) | [56] |
| Spinobulbar Muscular Atrophy (SBMA) or Kennedy disease | Motor neurons (anterior horn cells, bulbar neurons) and dorsal root ganglia | 11–34 | Androgen receptor (n, c) | [57] |
| Dentatorubral-pallidoluysian atrophy (DRPLA) | Globus pallidus, dentatorubral and subthalamic nucleus | 7–35 | Atrophin (n, c) | [58] |

Cellular localization: c, cytosolic; m, transmembrane; n, nuclear.

an assay that measures the incorporation of radioactive putrescine (amine donor) into N,N-dimethyl casein (amine acceptor), seems to be due to TG2 [65], no conclusive data has been obtained by TG2 gene knock-out experiments about the involvement of this TG in the development of the symptoms in HD-transgenic mice [66]. However, a recent scientific report showed that cystamine reduces aggregate formation in a mouse model of oculopharyngeal muscular dystrophy (OMPD), in which also the TG2 knockdown is capable to suppress the aggregation and the toxicity of the mutant protein PABPN1 [67], suggesting this compound as a possible therapeutic for OMPD.

### 6. Conclusions

Although many scientific reports have implicated aberrant TG activity in Alzheimer’s disease and other neurodegenerative diseases, still today we are looking for data which could definitely confirm the direct involvement of TGs in the pathogenetic mechanisms responsible for these diseases. The use of inhibitors of TGs could be then useful for experimental approaches. To minimize the possible side effects, however, selective inhibitors of the TGs should be required in the future. Progress in this area of research may be achieved also through pharmacogenetic techniques.

### Acknowledgment

This work is supported by the Italian Education Department.

### References

[1] J. E. Folk, “Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation,” *Advances in Enzymology and Related Areas of Molecular Biology*, vol. 54, pp. 1–56, 1983.
[2] L. Lorand and S. M. Conrad, “Transglutaminases,” *Molecular and Cellular Biochemistry*, vol. 58, no. 1-2, pp. 9–35, 1984.
[3] M. Fiorentini, N. Martino, S. Beninati, and J. E. Folk, “Free and protein-conjugated polyamines in mouse epidermal cells. Effect of high calcium and retinoic acid,” *Journal of Biological Chemistry*, vol. 263, no. 8, pp. 3790–3794, 1988.
[4] C. Y. Kim, H. Quarsten, E. Bergseng, C. Khosla, and L. M. Solli, “Structural basis for HLA-DQ2-mediated presentation
of gluten epitopes in celiac disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 12, pp. 4175–4179, 2004.

[5] B. Fleckenstein, S. W. Qiao, M. R. Larsen, G. Jung, P. Roepstorff, and L. M. Sollid, “Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides,” Journal of Biological Chemistry, vol. 279, no. 17, pp. 17607–17616, 2004.

[6] K. E. Achtman and C. S. Greenberg, “Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity,” Journal of Biological Chemistry, vol. 262, no. 4, pp. 1901–1906, 1987.

[7] G. Hasegawa, M. Suwa, Y. Ichikawa et al., “A novel function of tissue-type transglutaminase: protein disulphide isomerase,” Biochemical Journal, vol. 373, no. 3, pp. 793–803, 2003.

[8] J. Lahav, E. Karniel, Z. Bagoly, V. Sheptovitsky, R. Dardik, and A. Inbal, “Coagulation factor XIII serves as protein disulphide isomerase,” Thrombosis and Haemostasis, vol. 101, no. 5, pp. 840–844, 2009.

[9] S. E. Iismaa, B. M. Mearns, L. Lorand, and R. M. Graham, “Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders,” Physiological Reviews, vol. 89, no. 3, pp. 991–1023, 2009.

[10] B. Olaisen, T. Gedde-Dahl Jr., and P. Teisberg, “A structural locus for coagulation factor XIII (F13A) is located distal to the HLA region on chromosome 6p in man,” American Journal of Human Genetics, vol. 37, no. 1, pp. 215–220, 1985.

[11] K. Yamanishi, I. Inazawa, F. M. Liew et al., “Structure of the gene for human transglutaminase I,” Journal of Biological Chemistry, vol. 267, no. 25, pp. 17858–17863, 1992.

[12] V. Gentile, P. J. A. Davies, and A. Baldini, “The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization,” Genomics, vol. 20, no. 2, pp. 295–297, 1994.

[13] M. Wang, I. G. Kim, P. M. Steinert, and O. W. McBride, “Assignment of the human transglutaminase 2 (TGM2) and transglutaminase 3 (TGM3) genes to chromosome 20q11.2,” Genomics, vol. 23, no. 3, pp. 721–722, 1994.

[14] V. Gentile, F. J. Grant, R. Porta, and A. Baldini, “Localization of the human prostate transglutaminase (type IV) gene (TGM4) to chromosome 3p21.33–p22 by fluorescence in situ hybridization,” Genomics, vol. 27, no. 1, pp. 219–220, 1995.

[15] P. Grenard, M. K. Bates, and D. Aeschlimann, “Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15: structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z,” Journal of Biological Chemistry, vol. 276, no. 35, pp. 33066–33078, 2001.

[16] P. A. Smethurst and M. Griffin, “Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by Ca2+ and nucleotides,” Biochemical Journal, vol. 313, no. 3, pp. 803–808, 1996.

[17] H. Nakaoka, D. M. Perez, K. J. Baek et al., “Grα: a GTP-binding protein with transglutaminase activity and receptor signaling function,” Science, vol. 264, no. 5165, pp. 1393–1396, 1994.

[18] V. Gentile, R. Porta, E. Chiosi et al., “T1Gase/Gαh protein expression inhibits adenylate cyclase activity in Balb-C 3T3 fibroblasts membranes,” Biochimica et Biophysica Acta, vol. 1357, no. 1, pp. 115–122, 1997.

[19] N. Nanda, S. E. Iismaa, W. A. Owens, A. Husain, F. Mackay, and R. M. Graham, “Targeted inactivation of G/tissue transglutaminase II,” Journal of Biological Chemistry, vol. 276, no. 23, pp. 20673–20678, 2001.

[20] S. Mian, S. El Alaoui, J. Lawry, V. Gentile, P. J. A. Davies, and M. Griffin, “The importance of the GTP-binding protein tissue transglutaminase in the regulation of cell cycle progression,” FEBS Letters, vol. 370, no. 1-2, pp. 27–31, 1995.

[21] V. Thomazy and L. Fesus, “Differential expression of tissue transglutaminase in human cells. An immunohistochemical study,” Cell and Tissue Research, vol. 255, no. 1, pp. 215–224, 1989.

[22] C. D. C. Bailey and G. V. W. Johnson, “Developmental regulation of tissue transglutaminase in the mouse forebrain,” Journal of Neurochemistry, vol. 91, no. 6, pp. 1369–1379, 2004.

[23] S. Y. Kim, P. Grant, J. H. Lee, H. C. Pant, and P. M. Steinert, “Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer’s disease,” Journal of Biological Chemistry, vol. 274, no. 43, pp. 30715–30721, 1999.

[24] B. A. Citron, K. S. SantaCruz, P. J. A. Davies, and B. W. Festoff, “Intron-exon swapping of transglutaminase mRNA and neuronal tau aggregation in Alzheimer’s disease,” Journal of Biological Chemistry, vol. 276, no. 5, pp. 3295–3301, 2001.

[25] V. De Laurenzi and G. Melino, “Gene disruption of tissue transglutaminase,” Molecular and Cellular Biology, vol. 21, no. 1, pp. 148–155, 2001.

[26] L. Lorand and R. M. Graham, “Transglutaminases: crosslinking enzymes with pleiotropic functions,” Nature Reviews Molecular Cell Biology, vol. 4, no. 2, pp. 140–156, 2003.

[27] R. D. Adams and M. Victor, Principles of Neurology, McGraw-Hill, New York, NY, USA, 1993.

[28] D. J. Selkoe, Y. Ihara, and F. J. Salazar, “Alzheimer’s disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea,” Science, vol. 215, no. 4537, pp. 1243–1245, 1982.

[29] A. J. Griersson, G. V. W. Johnson, and C. C. J. Miller, “Three different human tau isoforms and rat neurofilament light, middle and heavy chain proteins are cellular substrates for transglutaminase,” Neuroscience Letters, vol. 298, no. 1, pp. 9–12, 2001.

[30] S. M. Dudek and G. V. W. Johnson, “Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of τ,” Journal of Neurochemistry, vol. 61, no. 3, pp. 1159–1162, 1993.

[31] M. L. Miller and G. V. W. Johnson, “Transglutaminase cross-linking of the τ protein,” Journal of Neurochemistry, vol. 65, no. 4, pp. 1760–1770, 1995.

[32] D. M. Appelt and B. J. Balin, “The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures,” Brain Research, vol. 745, no. 1-2, pp. 21–31, 1997.

[33] S. M. Singer, G. M. Zainelli, M. A. Norlund, J. M. Lee, and N. A. Muma, “Transglutaminase bonds in neurofilibrillary tangles and paired helical filament tau early in Alzheimer’s disease,” Neurochemistry International, vol. 40, no. 1, pp. 17–30, 2002.

[34] D. M. Appelt, G. C. Kopen, L. J. Boyne, and B. J. Balin, “Localization of transglutaminase in hippocampal neurons: implications for Alzheimer’s disease,” Journal of Histochemistry and Cytochemistry, vol. 44, no. 12, pp. 1421–1427, 1996.

[35] B. J. Balin, A. G. Loewy, and D. M. Appelt, “Analysis of transglutaminase-catalyzed isopeptide bonds in paired helical filaments and neurofilibrillary tangles from Alzheimer’s disease,” Methods in Enzymology, vol. 309, pp. 172–186, 1999.
[37] T. M. Jeitner, W. R. Matson, J. E. Folk, J. P. Blass, and A. J. L. Cooper, “Increased levels of γ-glutamylamines in Huntington disease CSF,” *Journal of Neurochemistry*, vol. 106, no. 1, pp. 37–44, 2008.

[38] S. M. Dudek and G. V. W. Johnson, “Transglutaminase facilitates the formation of polymers of the β-amyloid peptide,” *Brain Research*, vol. 651, no. 1-2, pp. 129–133, 1994.

[39] D. M. Hartley, C. Zhao, A. C. Speier et al., “Transglutaminase induces prototypil-like amyloid β-protein assemblies that are protease-resistant and inhibit long-term potentiation,” *Journal of Biological Chemistry*, vol. 283, no. 24, pp. 16790–16800, 2008.

[40] B. A. Citron, Z. Suo, K. SantaCruz, P. J. D. Davies, F. Qin, and B. W. Festoff, “Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration,” *Neurochemistry International*, vol. 40, no. 1, pp. 69–78, 2002.

[41] E. Junn, R. D. Ronchetti, M. M. Quezado, S. Y. Kim, and M. M. Mouradian, “Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 4, pp. 2047–2052, 2003.

[42] M. O. Zemaitaitis, J. M. Lee, J. C. Troncoso, and N. A. Muma, “Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy,” *Journal of Neuropathology and Experimental Neurology*, vol. 59, no. 11, pp. 983–989, 2000.

[43] M. O. Zemaitaitis, S. Y. Kim, R. A. Halverson, J. C. Troncoso, J. M. Lee, and N. A. Muma, “Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy,” *Journal of Neuropathology and Experimental Neurology*, vol. 62, no. 2, pp. 173–184, 2003.

[44] S. Iuchi, G. Hoffner, P. Verbeke, P. Djian, and H. Green, “Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamin,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 5, pp. 2409–2414, 2003.

[45] V. Gentile, C. Sepe, M. Calvani et al., “Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases,” *Archives of Biochemistry and Biophysics*, vol. 352, no. 2, pp. 314–321, 1998.

[46] P. Kahlem, H. Green, and P. Djian, “Transglutaminase action imitates Huntington's disease: selective polymerization of huntingtin containing expanded polyglutamine,” *Molecular Cell*, vol. 1, no. 4, pp. 595–601, 1998.

[47] M. V. Karpj, H. Garren, H. Slunt et al., “Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 13, pp. 7388–7393, 1999.

[48] L. G. Verhoeof, K. Lindsten, M. G. Masucci, and N. P. Dantuma, “Aggregate formation inhibits proteasomal degradation of polyglutamine proteins,” *Human Molecular Genetics*, vol. 11, no. 22, pp. 2689–2700, 2002.

[49] M. E. MacDonald, C. M. Ambrose, M. P. Duyao et al., “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes,” *Cell*, vol. 72, no. 6, pp. 971–983, 1993.

[50] S. Banfi, M. Y. Chung, T. J. Kwiatkowski et al., “Mapping and cloning of the critical region for the spinocerebellar ataxia type 1 gene (SCA1) in a yeast artificial chromosome contig spanning 1.2 Mb,” *Genomics*, vol. 18, no. 3, pp. 627–635, 1993.

[51] K. Sanpei, H. Takano, S. Igarashi et al., “Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT,” *Nature Genetics*, vol. 14, no. 3, pp. 277–284, 1996.

[52] M. A. Pujana, V. Volpini, and X. Estivill, “Large CAG/CTG repeat templates produced by PCR, usefulness for the DIRECT method of cloning genes with CAG/CTG repeat expansions,” *Nucleic Acids Research*, vol. 26, no. 5, pp. 1352–1353, 1998.

[53] C. E. Fletcher, C. M. Lutz, T. N. O'Sullivan et al., “Absence epilepsy in tottering mutant mice is associated with calcium channel defects,” *Cell*, vol. 87, no. 4, pp. 607–617, 1996.

[54] J. B. Vincent, M. L. Neves-Pereira, A. D. Paterson et al., “An unstable trinucleotide-repeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus,” *American Journal of Human Genetics*, vol. 66, no. 3, pp. 819–829, 2000.

[55] S. E. Holmes, E. O'Hearn, and R. L. Margolis, “Why is SCA12 different from other SCAs?” *Cytogenetic and Genome Research*, vol. 100, no. 1–4, pp. 189–197, 2003.

[56] G. Imbret, Y. Trotter, J. Beckmann, and J. L. Mandel, “The gene for the TATA binding protein (TBP) that contains a highly polymorphic protein coding CAG repeat maps to 6q27,” *Genomics*, vol. 21, no. 3, pp. 667–668, 1994.

[57] A. R. La Spada, E. M. Wilson, D. B. Lubahn, A. E. Harding, and K. H. Fischbeck, “Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy,” *Nature*, vol. 352, no. 6330, pp. 77–79, 1991.

[58] O. Onodera, M. Oyake, H. Takano, T. Ikeuchi, S. Igarashi, and S. Tsuji, “Molecular cloning of a full-length cDNA for dentatorubral-pallidolysian atrophy and regional expressions of the expanded alleles in the CNS,” *American Journal of Human Genetics*, vol. 57, no. 5, pp. 1050–1060, 1995.

[59] O. W. Griffith, A. Larsson, and A. Meister, “Inhibition of γ-glutamylcysteine synthetase by cystamine: an approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria),” *Biochemical and Biophysical Research Communications*, vol. 79, no. 3, pp. 919–925, 1977.

[60] S. Igarashi, R. Koide, T. Shimohata et al., “Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch,” *Nature Genetics*, vol. 18, no. 2, pp. 111–117, 1998.

[61] M. V. Karpj, M. W. Becher, J. E. Springer et al., “Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine,” *Nature Medicine*, vol. 8, no. 2, pp. 143–149, 2002.

[62] A. Dedegolu, J. K. Kubilus, T. M. Jeitner et al., “Therapeutic effects of cystamine in a murine model of Huntington's disease,” *Journal of Neuroscience*, vol. 22, no. 20, pp. 8942–8950, 2002.

[63] M. Lesort, M. Lee, J. Tucholski, and G. V. W. Johnson, “Cystamine inhibits caspase activity: implications for the treatment of polyglutamine disorders,” *Journal of Biological Chemistry*, vol. 278, no. 6, pp. 3825–3830, 2003.
[65] B. F. Krasnikov, S. Y. Kim, S. J. McConoughey et al., “Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria,” Biochemistry, vol. 44, no. 21, pp. 7830–7843, 2005.

[66] P. G. Mastroberardino, C. Iannicola, R. Nardacci et al., “‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington’s disease,” Cell Death and Differentiation, vol. 9, no. 9, pp. 873–880, 2002.

[67] J. E. Davies, C. Rose, S. Sarkar, and D. C. Rubinszttein, “Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy,” Science Translational Medicine, vol. 2, no. 34, pp. 34–40, 2010.